Research ExplorerPublicationsImpact of zoledronic acid on control of metastatic spinal co...

Impact of zoledronic acid on control of metastatic spinal cord compression.

Standard

Impact of zoledronic acid on control of metastatic spinal cord compression. / Rades, D; Hakim, S G; Bajrovic, Amira; Karstens, J H; Veninga, T; Rudat, V; Schild, S E.

In: STRAHLENTHER ONKOL, Vol. 188, No. 10, 10, 2012, p. 910-916.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Hakim, SG, Bajrovic, A, Karstens, JH, Veninga, T, Rudat, V & Schild, SE 2012, 'Impact of zoledronic acid on control of metastatic spinal cord compression.', STRAHLENTHER ONKOL, vol. 188, no. 10, 10, pp. 910-916. <http://www.ncbi.nlm.nih.gov/pubmed/22903395?dopt=Citation>

APA

Rades, D., Hakim, S. G., Bajrovic, A., Karstens, J. H., Veninga, T., Rudat, V., & Schild, S. E. (2012). Impact of zoledronic acid on control of metastatic spinal cord compression. STRAHLENTHER ONKOL, 188(10), 910-916. [10]. http://www.ncbi.nlm.nih.gov/pubmed/22903395?dopt=Citation

Vancouver

Rades D, Hakim SG, Bajrovic A, Karstens JH, Veninga T, Rudat V et al. Impact of zoledronic acid on control of metastatic spinal cord compression. STRAHLENTHER ONKOL. 2012;188(10):910-916. 10.

Bibtex

@article{1ade6d5fedf0484abc1644113d622333,
title = "Impact of zoledronic acid on control of metastatic spinal cord compression.",
abstract = "Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).",
keywords = "Comorbidity, Humans, Male, Aged, Female, Middle Aged, Risk Factors, Treatment Outcome, Survival Analysis, Survival Rate, Prevalence, Germany/epidemiology, Diphosphonates/*therapeutic use, Bone Density Conservation Agents/administration & dosage, Chemotherapy, Adjuvant/methods/mortality, Imidazoles/*therapeutic use, Radiotherapy, Conformal/*mortality, Spinal Cord Compression/*drug therapy/mortality/*prevention & control, Spinal Neoplasms/mortality/*secondary/*therapy, Comorbidity, Humans, Male, Aged, Female, Middle Aged, Risk Factors, Treatment Outcome, Survival Analysis, Survival Rate, Prevalence, Germany/epidemiology, Diphosphonates/*therapeutic use, Bone Density Conservation Agents/administration & dosage, Chemotherapy, Adjuvant/methods/mortality, Imidazoles/*therapeutic use, Radiotherapy, Conformal/*mortality, Spinal Cord Compression/*drug therapy/mortality/*prevention & control, Spinal Neoplasms/mortality/*secondary/*therapy",
author = "D Rades and Hakim, {S G} and Amira Bajrovic and Karstens, {J H} and T Veninga and V Rudat and Schild, {S E}",
year = "2012",
language = "English",
volume = "188",
pages = "910--916",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "10",

}

RIS

TY - JOUR

T1 - Impact of zoledronic acid on control of metastatic spinal cord compression.

AU - Rades, D

AU - Hakim, S G

AU - Bajrovic, Amira

AU - Karstens, J H

AU - Veninga, T

AU - Rudat, V

AU - Schild, S E

PY - 2012

Y1 - 2012

N2 - Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).

AB - Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).

KW - Comorbidity

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Risk Factors

KW - Treatment Outcome

KW - Survival Analysis

KW - Survival Rate

KW - Prevalence

KW - Germany/epidemiology

KW - Diphosphonates/therapeutic use

KW - Bone Density Conservation Agents/administration & dosage

KW - Chemotherapy, Adjuvant/methods/mortality

KW - Imidazoles/therapeutic use

KW - Radiotherapy, Conformal/mortality

KW - Spinal Cord Compression/drug therapy/mortality/prevention & control

KW - Spinal Neoplasms/mortality/secondary/therapy

KW - Comorbidity

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Risk Factors

KW - Treatment Outcome

KW - Survival Analysis

KW - Survival Rate

KW - Prevalence

KW - Germany/epidemiology

KW - Diphosphonates/therapeutic use

KW - Bone Density Conservation Agents/administration & dosage

KW - Chemotherapy, Adjuvant/methods/mortality

KW - Imidazoles/therapeutic use

KW - Radiotherapy, Conformal/mortality

KW - Spinal Cord Compression/drug therapy/mortality/prevention & control

KW - Spinal Neoplasms/mortality/secondary/therapy

M3 - SCORING: Journal article

VL - 188

SP - 910

EP - 916

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 10

M1 - 10

ER -